These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 36586158)
1. Synergy of oral recombinant methioninase (rMETase) and 5-fluorouracil on poorly differentiated gastric cancer. Miyake M; Miyake K; Han Q; Igarashi K; Kawaguchi K; Barangi M; Kiyuna T; Sugisawa N; Higuchi T; Oshiro H; Zhang Z; Razmjooei S; Bouvet M; Endo I; Hoffman RM Biochem Biophys Res Commun; 2023 Feb; 643():48-54. PubMed ID: 36586158 [TBL] [Abstract][Full Text] [Related]
2. Recombinant Oral Methioninase (o-rMETase) Combined With Oxaliplatinum Plus 5-Fluorouracil Improves Survival of Mice With Massive Colon-Cancer Peritoneal Carcinomatosis. Kim MJ; Han Q; Bouvet M; Hoffman RM; Park JH Anticancer Res; 2023 Jan; 43(1):19-24. PubMed ID: 36585181 [TBL] [Abstract][Full Text] [Related]
3. Combining Tumor-Selective Bacterial Therapy with Salmonella typhimurium A1-R and Cancer Metabolism Targeting with Oral Recombinant Methioninase Regressed an Ewing's Sarcoma in a Patient-Derived Orthotopic Xenograft Model. Miyake K; Kiyuna T; Li S; Han Q; Tan Y; Zhao M; Oshiro H; Kawaguchi K; Higuchi T; Zhang Z; Razmjooei S; Barangi M; Wangsiricharoen S; Murakami T; Singh AS; Li Y; Nelson SD; Eilber FC; Bouvet M; Hiroshima Y; Chishima T; Matsuyama R; Singh SR; Endo I; Hoffman RM Chemotherapy; 2018; 63(5):278-283. PubMed ID: 30673664 [TBL] [Abstract][Full Text] [Related]
4. Oral recombinant methioninase combined with paclitaxel arrests recalcitrant ovarian clear cell carcinoma growth in a patient-derived orthotopic xenograft (PDOX) nude-mouse model. Sugisawa N; Higuchi T; Han Q; Hozumi C; Yamamoto J; Tashiro Y; Nishino H; Kawaguchi K; Bouvet M; Murata T; Unno M; Hoffman RM Cancer Chemother Pharmacol; 2021 Jul; 88(1):61-67. PubMed ID: 33768300 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of recombinant methioninase in combination with cisplatin on human colon tumors in nude mice. Tan Y; Sun X; Xu M; Tan X; Sasson A; Rashidi B; Han Q; Tan X; Wang X; An Z; Sun FX; Hoffman RM Clin Cancer Res; 1999 Aug; 5(8):2157-63. PubMed ID: 10473100 [TBL] [Abstract][Full Text] [Related]
6. Oral recombinant methioninase combined with oxaliplatinum and 5-fluorouracil regressed a colon cancer growing on the peritoneal surface in a patient-derived orthotopic xenograft mouse model. Park JH; Han Q; Zhao M; Tan Y; Higuchi T; Yoon SN; Sugisawa N; Yamamoto J; Bouvet M; Clary B; Singh SR; Hoffman RM Tissue Cell; 2019 Dec; 61():109-114. PubMed ID: 31759402 [TBL] [Abstract][Full Text] [Related]
7. Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer. Kawaguchi K; Miyake K; Han Q; Li S; Tan Y; Igarashi K; Lwin TM; Higuchi T; Kiyuna T; Miyake M; Oshiro H; Bouvet M; Unno M; Hoffman RM Cell Cycle; 2018; 17(7):868-873. PubMed ID: 29623758 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of oral recombinant methioninase combined with oxaliplatinum and 5-fluorouracil on primary colon cancer in a patient-derived orthotopic xenograft mouse model. Park JH; Zhao M; Han Q; Sun Y; Higuchi T; Sugisawa N; Yamamoto J; Singh SR; Clary B; Bouvet M; Hoffman RM Biochem Biophys Res Commun; 2019 Oct; 518(2):306-310. PubMed ID: 31421825 [TBL] [Abstract][Full Text] [Related]
9. Oral-recombinant Methioninase in Combination With Rapamycin Eradicates Osteosarcoma of the Breast in a Patient-derived Orthotopic Xenograft Mouse Model. Masaki N; Han Q; Samonte C; Wu NF; Hozumi C; Wu J; Obara K; Kubota Y; Aoki Y; Bouvet M; Hoffman RM Anticancer Res; 2022 Nov; 42(11):5217-5222. PubMed ID: 36288875 [TBL] [Abstract][Full Text] [Related]
12. Tumor-targeting Salmonella typhimurium A1-R combined with recombinant methioninase and cisplatinum eradicates an osteosarcoma cisplatinum-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: decoy, trap and kill chemotherapy moves toward the clinic. Igarashi K; Kawaguchi K; Kiyuna T; Miyake K; Miyake M; Li S; Han Q; Tan Y; Zhao M; Li Y; Nelson SD; Dry SM; Singh AS; Elliott IA; Russell TA; Eckardt MA; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Eilber FC; Hoffman RM Cell Cycle; 2018; 17(6):801-809. PubMed ID: 29374999 [TBL] [Abstract][Full Text] [Related]
13. Anticancer efficacy in vivo and in vitro, synergy with 5-fluorouracil, and safety of recombinant methioninase. Yoshioka T; Wada T; Uchida N; Maki H; Yoshida H; Ide N; Kasai H; Hojo K; Shono K; Maekawa R; Yagi S; Hoffman RM; Sugita K Cancer Res; 1998 Jun; 58(12):2583-7. PubMed ID: 9635582 [TBL] [Abstract][Full Text] [Related]
14. Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma. Igarashi K; Kawaguchi K; Li S; Han Q; Tan Y; Murakami T; Kiyuna T; Miyake K; Miyake M; Singh AS; Eckardt MA; Nelson SD; Russell TA; Dry SM; Li Y; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Singh SR; Eilber FC; Hoffman RM Cancer Lett; 2018 Mar; 417():168-173. PubMed ID: 29306021 [TBL] [Abstract][Full Text] [Related]
15. Oral-recombinant Methioninase Converts an Osteosarcoma from Methotrexate-resistant to -sensitive in a Patient-derived Orthotopic-xenograft (PDOX) Mouse Model. Aoki Y; Tome Y; Han Q; Yamamoto J; Hamada K; Masaki N; Kubota Y; Bouvet M; Nishida K; Hoffman RM Anticancer Res; 2022 Feb; 42(2):731-737. PubMed ID: 35093871 [TBL] [Abstract][Full Text] [Related]
16. Extensive Shrinkage and Long-term Stable Disease in a Teenage Female Patient With High-grade Glioma Treated With Temozolomide and Radiation in Combination With Oral Recombinant Methioninase and a Low-methionine Diet. Sato M; Han Q; Mizuta K; Mori R; Kang BM; Morinaga S; Kobayashi N; Ichikawa Y; Nakajima A; Hoffman RM In Vivo; 2024; 38(3):1459-1464. PubMed ID: 38688589 [TBL] [Abstract][Full Text] [Related]
17. Growth of doxorubicin-resistant undifferentiated spindle-cell sarcoma PDOX is arrested by metabolic targeting with recombinant methioninase. Igarashi K; Li S; Han Q; Tan Y; Kawaguchi K; Murakami T; Kiyuna T; Miyake K; Li Y; Nelson SD; Dry SM; Singh AS; Elliott IA; Russell TA; Eckardt MA; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Eilber FC; Hoffman RM J Cell Biochem; 2018 Apr; 119(4):3537-3544. PubMed ID: 29143983 [TBL] [Abstract][Full Text] [Related]
18. Oral-recombinant Methioninase Lowers the Effective Dose and Eliminates Toxicity of Cisplatinum for Primary Osteosarcoma of the Mammary Gland in a Patient-derived Orthotopic Xenograft Mouse Model. Masaki N; Han Q; Wu NF; Samonte C; Wu J; Hozumi C; Obara K; Kubota Y; Aoki Y; Miyazaki J; Hoffman RM In Vivo; 2022; 36(6):2598-2603. PubMed ID: 36309364 [TBL] [Abstract][Full Text] [Related]
19. Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and prevention. Kawaguchi K; Han Q; Li S; Tan Y; Igarashi K; Kiyuna T; Miyake K; Miyake M; Chmielowski B; Nelson SD; Russell TA; Dry SM; Li Y; Singh AS; Eckardt MA; Unno M; Eilber FC; Hoffman RM Cell Cycle; 2018; 17(3):356-361. PubMed ID: 29187018 [TBL] [Abstract][Full Text] [Related]
20. Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model. Murakami T; Li S; Han Q; Tan Y; Kiyuna T; Igarashi K; Kawaguchi K; Hwang HK; Miyake K; Singh AS; Nelson SD; Dry SM; Li Y; Hiroshima Y; Lwin TM; DeLong JC; Chishima T; Tanaka K; Bouvet M; Endo I; Eilber FC; Hoffman RM Oncotarget; 2017 May; 8(22):35630-35638. PubMed ID: 28404944 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]